Beta Bionics, Inc. is under investigation by Grabar Law Office for alleged breaches of fiduciary duty related to misleading shareholders about serious FDA concerns over its iLet insulin delivery device. The FDA reportedly found thousands of complaints about the device malfunctioning and causing dangerous hypoglycemic events, which Beta Bionics allegedly downplayed. Following disclosures of these issues, Beta Bionics' stock price dropped significantly. Shareholders who bought shares before July 30, 2025, and still hold them may seek corporate reforms and compensation through the investigation.
Coffee Holding Co. reported a strong third-quarter earnings per share of $0.35, far surpassing analyst expectations, signaling robust profitability. However, revenue declined to $21.69 million, missing estimates due to falling green coffee prices and...
An analyst from DA Davidson reduced the price target for Brinker International to $240 from $260, reflecting a 12.64% potential upside from the current trading price of $213.06. This adjustment follows a 10% share decline over the past month, althoug...
Telsey Advisory maintained a Market Perform rating for RH, a luxury home furnishings company, after its mixed Q2 results. RH reported strong earnings of $2.70 per share, beating estimates significantly, but its revenue of $922.15 million fell short o...
Gossamer Bio, a clinical-stage biopharmaceutical company, executed an 80-for-1 reverse stock split on September 11, 2026, consolidating its shares to increase the price per share. This move, approved by the board and effective from September 10, aims...
New Fortress Energy will execute a 1-for-50 reverse stock split on September 14, 2026, to increase its share price and comply with Nasdaq's minimum $1.00 bid price requirement. Currently trading at $0.33, the company aims to avoid delisting by consol...
